Finasteride vs dutasteride for hair loss: the honest 2026 comparison
Dutasteride blocks DHT more completely than finasteride. It's also off-label for hair, has weaker safety data, and costs more. When the trade-off makes sense.
By GLPZoom Editorial
2 min readUpdated
Jump to section
Finasteride is FDA-approved for male-pattern hair loss at 1mg/day. Dutasteride is FDA-approved for benign prostatic hyperplasia at 0.5mg/day, and used off-label for hair at the same dose. Both block the enzyme (5-alpha reductase) that converts testosterone to DHT. Dutasteride blocks both isoforms; finasteride only one. Result: dutasteride suppresses DHT by ~90%, finasteride by ~70%.
Does the bigger DHT suppression mean better hair outcomes
Modestly, yes. Head-to-head trials show dutasteride produces about 1.5x the hair-count increase of finasteride at 6 months. Patients who plateaued on finasteride often see additional improvement when switched to dutasteride.
The trade-off: side-effect profile. The same sexual side effects reported on finasteride (decreased libido, ED, ejaculation issues, mood changes) occur on dutasteride at higher rates in some studies, lower in others. The evidence base for dutasteride is much smaller — fewer trials, shorter follow-up, less long-term safety data.
When to consider dutasteride
You've been on finasteride for at least 12 months. You're getting some response but want more. You've discussed off-label risks with a prescribing clinician. You can afford the higher monthly cost ($45-90 compared to $15-30 for finasteride).
When NOT to consider it: as a first-line therapy, without trying finasteride first. The marginal benefit doesn't justify the marginal risk before you know how your body responds to the lighter DHT suppression.
Telehealth availability
Most US telehealth platforms prescribe finasteride routinely. Dutasteride is hit-or-miss — Hims, Keeps, and Roman will prescribe; some platforms refer out. Compounded topical dutasteride (lower systemic absorption, theoretically lower side-effect risk) is the newest option — small evidence base, but promising.